Skip to main content

Table 2 The sites of initial disease progression after response to gefitinib

From: Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer

Site No. of patients %
Primary lesion 8 29.6
Metastatic lesion   
   Intrapulmonary 8 29.6
   Pleural effusion 6 22.2
   Bone 5 18.5
   CNS 3 11.1
   Others 0 0
  1. CNS, central nervous system